The Changing Face of Tardive Dyskinesia Treatment Options: Update for Neurologic and Psychiatric Pharmacists

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Jul 21, 2017
  • Expires: Jul 21, 2018
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Click Here to Complete Activity

Faculty

Steven Stoner Steven Stoner, PharmD, BCPP
Chair and Clinical Professor
University of Missouri Kansas City
School of Pharmacy
Division of Pharmacy Practice and Administration
Kansas City, MO

Needs Statement

Psychiatric and neurologic pharmacists are actively involved in the care of patients with long-standing psychiatric illness, many of whom receive antipsychotic medications for extended periods of time. Trained specialty pharmacists have been shown to assess abnormal movements at a skill level comparable to trained physicians and are ideally positioned to assist in the documentation of AIMS/DISCUS scores for the patient at risk. They also may be a primary provider for treatment decisions or part of the treatment team and can guide optimal medication selection. CPNP attendees will review new data with clinical experts and interact via patient cases to ensure they are current with their assessment techniques and knowledgeable about new treatment options.

Target Audience

This activity is designed to meet the educational needs of psychiatric and neurologic pharmacists who treat patients with tardive dyskinesia (TD).

Objectives

At the conclusion of this knowledge-based activity, participants should be able to:

  • Outline risk factors for development of tardive dyskinesia in the psychiatric setting.
  • Assess new onset or progression of movement symptoms in patients at risk for tardive dyskinesia.
  • Identify treatment options for tardive dyskinesia in the psychiatric patient, using evidence-based and emerging therapies with the highest degree of demonstrated efficacy and safety.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in edu­cational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide partici­pants with information that might be of potential importance to their evaluation of a presentation.

Planner
Joan B. Fowler, PharmD, BCPP
has no relevant financial relationships to disclose in relation to the content of this activity.

Author/Presenter
Steven Stoner, PharmD, BCPP
has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer
Leigh Anne Nelson, PharmD, BCPP
has no relevant financial relationships to disclose in relation to the content of this activity.